184 related articles for article (PubMed ID: 20388222)
21. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
22. Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.
Akcay T; Yasar O; Kuseyri MA; Dincer Y; Aydinli K; Benian A; Balcan E; Erenel H
Bratisl Lek Listy; 2016; 117(3):156-60. PubMed ID: 26925746
[TBL] [Abstract][Full Text] [Related]
23. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
24. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
26. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
[TBL] [Abstract][Full Text] [Related]
27. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
28. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
[TBL] [Abstract][Full Text] [Related]
29. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
Rauvala M; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
[TBL] [Abstract][Full Text] [Related]
30. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
Piatek S; Panek G; Lewandowski Z; Bidzinski M; Piatek D; Kosinski P; Wielgos M
J Ovarian Res; 2020 Sep; 13(1):102. PubMed ID: 32878632
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
Li XP; Xu QY; Wang JL; Wang SJ; Zhao Y; Wei LH
Chin Med J (Engl); 2012 Feb; 125(3):410-5. PubMed ID: 22490394
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
[TBL] [Abstract][Full Text] [Related]
34. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
[TBL] [Abstract][Full Text] [Related]
35. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
36. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
[TBL] [Abstract][Full Text] [Related]
37. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.
Shimogai R; Kigawa J; Itamochi H; Iba T; Kanamori Y; Oishi T; Shimada M; Sato S; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2008; 18(3):499-505. PubMed ID: 18476949
[TBL] [Abstract][Full Text] [Related]
38. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
39. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
[TBL] [Abstract][Full Text] [Related]
40. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
